• 1
    Fukuto JM, Cho JY, Switzer CH. The chemical properties of nitric oxide and related nitrogen oxides. In: IgnarroLJ, ed. Nitric Oxide: Biology and Pathobiology. San Diego, CA: Academic Press, 2000; 2339.
  • 2
    Feelisch M, Noack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987; 139: 1930.
  • 3
    Chen Z, Stamler JS. Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med 2006; 16: 25965.
  • 4
    Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 638792.
  • 5
    Maeda H, Noguchi Y, Sato K, Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994; 85: 3314.
  • 6
    Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and nitric oxide scavenger. Cancer Res 1998; 58: 15965.
  • 7
    Seki T, Fang J, Maeda H. Tumor targeted macromolecular drug delivery based on the enhanced permeability and retention effect in solid tumor. In: LuY, MahatoRI, eds. Pharmaceutical Perspectives of Cancer Therapeutics. New York: AAPS-Springer, 2009; 9312.
  • 8
    Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001; 74: 4761.
  • 9
    Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46: 16985.
  • 10
    Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003; 42: 1089105.
  • 11
    Li CJ, Miyamoto Y, Kojima Y, Maeda H. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer 1993; 67: 97580.
  • 12
    Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor targeted delivery of macromolecular drug SMANCS: Cases of advanced solid tumors. Jpn J Clin Oncol 2009; doi: 10.1093/jjco/hyp074.
  • 13
    Sahoo SK, Sawa T, Fang J et al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug Chem 2002; 13: 10318.
  • 14
    Fang J, Sawa T, Akaike T et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 2003; 63: 356774.
  • 15
    Fang J, Sawa T, Akaike T, Greish K, Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer 2004; 109: 18.
  • 16
    Jordan BF, Misson P-D, Demeure R et al. Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000; 48 (2): 56570.
  • 17
    Mitchell JB, Wink DA, DeGraff W et al. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 1993; 53 (24): 58458.
  • 18
    Frérart F, Sonveaux P, Rath G et al. The acidic tumor microenvironment promotes the reconversion of nitrite into nitric oxide: towards a new and safe radiosensitizing strategy. Clin Cancer Res 2008; 14: 276874.
  • 19
    Yasuda H, Nakayama K, Watanabe M et al. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res 2006; 12: 674857.
  • 20
    Yasuda H, Yanagihara K, Nakayama K et al. Therapeutic applications of nitric oxide for malignant tumor in animal models and human studies. In: BonavidaB, ed. Nitric Oxide and Cancer. New York: Springer Science, 2009 (in press).